GlobeNewswire

Business Master's Degree Not a Substitute for an MBA

Dela

RESTON, Va., May 16, 2017 (GLOBE NEWSWIRE) -- Three in 4 prospective graduate business school candidates who hold a prior master's degree are considering enrolling in MBA programs, according to new research from the Graduate Management Admission Council (GMAC). Findings from the Council's 2017 mba.com Prospective Students Survey Report released today show that the MBA remains the predominant program format considered by candidates with both prior business master's degrees (61 percent) and non-business master's degrees (86 percent).

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0d5fa2ea-6ea2-4f4e-8fcb-38ffc02b4070

"These findings demonstrate that a business master's degree is not necessarily the end of graduates' business education," said Sangeet Chowfla, president and CEO of GMAC. "For many, their business master's degree is a stepping stone to continued professional development that may include an MBA down the road, in either a full-time or part-time format."

The findings of the mba.com Prospective Students Survey Report show that globally 22 percent of prospective business school candidates have a prior master's degree, with considerable regional variation. While 2 in 5 European candidates have a prior master's-level credential, the same is true of just 14 percent of U.S. candidates.

Key Findings

Demand for Business Master's Programs Continues to Grow

Fueled by growing candidate demand, non-MBA business master's programs continue to proliferate. Globally, the percentage of candidates considering only business master's degrees - such as Master of Finance, Master of Accounting, and Master in Management - has increased from 15 percent in 2009 to 23 percent in 2016. This rise in interest has been particularly strong among candidates from East and Southeast Asia and Western Europe, where now more than 2 in 5 candidates report considering only these program types.

Non-MBA programs and MBA programs attract distinct candidate pools seeking different outcomes. Candidates considering non-MBA business master's programs skew younger and the majority have little to no prior work experience. Compared with MBA candidates, individuals preferring business master's programs are more interested in developing their technical skills. MBA candidates are typically older, have more years of work experience, and are more interested in developing their managerial and leadership skills. 

International Study Demand Remains Strong

Nearly 3 in 5 prospective business school students (59 percent) intend to apply to programs outside their country of residence, up from 44 percent in 2009. Most candidates seek study opportunities outside their country of citizenship to receive a higher-quality education (63 percent of respondents), to increase their chance of securing international employment (58 percent), and to expand their international connections (51 percent). One-third (34 percent) of candidates who prefer to study outside their country of citizenship intend to seek employment in the country where they prefer to attend school.

U.S. Remains Most Preferred Study Destination Though Candidate Preferences Are Shifting

Consistent with past research, more than 9 in 10 U.S. candidates prefer to study domestically (96 percent). Globally, among full-time MBA candidates looking to study outside their country of citizenship, 58 percent prefer to study in the U.S., down from 61 percent in 2009. Since 2009, there has been an increase in MBA candidates preferring to study in Canada (4 percent in 2009 vs. 7 percent in 2016).

There has been a similar shift in preferred study destinations among non-U.S. candidates interested in business master's programs. In 2016, 47 percent of non-U.S. prospective students interested in business master's programs expressed a preference for study in the U.S., down from 57 percent in 2009. Over time, a greater share of these candidates have shown interest in applying to programs in Western Europe (34 percent in 2016 vs. 30 percent in 2009), Canada (7 percent in 2016 vs. 4 percent (2009), and East and Southeast Asia (7 percent in 2016 vs. 4 percent in 2009).

Recent Immigration Policy Changes Having Impact on International Study Choices

Recent shifts in immigration policies may impact candidates' study destination preferences in 2017. Anticipated changes in U.S. immigration policies and last year's Brexit vote in the United Kingdom may make it more difficult for non-citizens to obtain student visas to study in those countries or to obtain work visas after graduation to seek employment, one of the main reasons for studying in those countries.

Since November 2016, a growing share of international candidates say they are now less likely to pursue a graduate business degree in the U.S. due to the U.S. presidential election results. The percentage of non-U.S. citizen mba.com registrants who say they are now less likely to study in the U.S. has grown from 35 percent in November 2016 to 43 percent in April 2017.

Early indications are that the British Brexit vote to leave the European Union may negatively impact international candidate demand to apply to U.K. business schools. In December 2016, among nearly 1,300 non-U.K. GMAT test takers surveyed about the Brexit vote, 45 percent indicated that the Brexit vote has made them less likely to study in the U.K. A country-level analysis reveals that Indian candidates are the most negatively influenced by the Brexit vote, with 58 percent reporting that it has made them less likely to study in the U.K. GMAC launched a second survey of non-U.K. GMAT test takers on March 29, the day the U.K. triggered Article 50 of the Treaty of Lisbon, which allows the U.K. to unilaterally quit the European Union. This survey closed on April 7 and showed the same percentage of candidates would be less likely to study in the U.K.

Education Costs and Financing Continue to Weigh Heavily on Candidates' Minds

The predominant reservation candidates have about pursuing a graduate business education revolves around costs. Approximately half of surveyed candidates indicate that not having enough money available to pay for their education (52 percent of respondents) and potentially having to take on large debts (47 percent) may prevent them from pursuing a graduate business degree.

The two most important financial aspects that candidates evaluate when deciding where to apply are total tuition costs and scholarship availability. Compared with 2009, candidates, on average, expect to cover a greater share of the cost of their education with grants, fellowships, and scholarships and a smaller share with parental support, loans, and employer assistance.

Analysis in the 2017 mba.com Prospective Students Survey Report is based on survey responses provided by 11,617 individuals who registered on mba.com between February and December 2016. To download the full report visit: gmac.com/prospectivestudents. For supporting graphics, visit the  GMAC News Center .

About GMAC: The Graduate Management Admission Council (GMAC) is a global, nonprofit association of 220 leading graduate business schools. Founded in 1953, we are actively committed to advancing the art and science of admissions by convening and representing the industry and offering best-in-class products and services for schools and students. GMAC owns and administers the Graduate Management Admission Test® (GMAT®), used by more than 6,500 graduate programs worldwide, and the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India. The Council is based in Reston, Va., with offices in London, New Delhi (Gurgaon) and Hong Kong. For information on assessments, study tools and services for candidates, visit www.mba.com. For information about The Council and our market intelligence, professional development opportunities and services for graduate management education, please visit www.gmac.com

MEDIA CONTACT:  
Jennifer Garfinkel; Director of Media Relations, GMAC
+1 (703) 668-9805 or jgarfinkel@gmac.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum